CEO O’Connell, CMO Siemers & CFO Zuga discuss the topline results from Acumen’s Phase 1 INTERCEPT-AD Trial in early Alzheimer’s Disease on a conference call to be held on July 17 at 8 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABOS:
- Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Acumen Pharma (NASDAQ:ABOS) Skyrockets on Promising Phase 1 Data in Alzheimer’s Disease
- Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease
- Acumen holds a conference call
- Acumen presents topline results from first-in-human Phase 1 study of ACU193
